Global Anti-Cancer Drug Market By Product Type (Avastin, Rituxan) And By End-Users/Application (Hospital, Clinic) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-800493
  • January 2021
  • Pharmaceuticals
  • 103 Pages
According to Apex Market Research the Anti-Cancer Drug market was valued at USD xx.xx million in 2019 and is anticipated to grow at a CAGR of xx% during the forecast period from 2020 to 2028. The report on Anti-Cancer Drug market delivers detailed analysis covering major regional trends, market dynamics, and offer country-level market value of Anti-Cancer Drug industry. Some of the major aspects considered during the course of research comprises definition of the product, classification of the product, industry structure, different participants in the Anti-Cancer Drug ecosystem, etc. The report comprises of market value and forecast for the period from 2020 to 2028, CAGR measured for individual segment and regional market, competitive landscape of key market players, and profiling of major providers participating in the Anti-Cancer Drug market.

The following manufacturers are covered in this report:
  • Merck
  • Bristol-Myers Squibb
  • Bayer
  • GlaxoSmithKline
  • Novartis
  • Sanofi
  • Pfizer
  • Amgen
  • Celgene Corporation
  • Ariad Pharmaceuticals
  • Eli Lilly
  • Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceuticals

The report estimates on the Anti-Cancer Drug market economy trend, market numbers (Mn/Bn USD) and CAGR from the 2020-2028, considering 2019 as the base year. A global Anti-Cancer Drug market report consist of all leading industry players, Anti-Cancer Drug business sections, company profile, revenue supply by Anti-Cancer Drug industry sections, global Anti-Cancer Drug market trends, acquisitions and arrangements, contact info, recent development, geographic examination and even more using the assistance.

Since the onset of COVID-19 in December 2019, the governments of various countries declared lockdown and as result numerous economies around the world experienced severe economic downturn. Since early 2020, the Anti-Cancer Drug market witnessed the impact of COVID-19 The report objects to provide pre-COVID-19 state of the Anti-Cancer Drug market in years 2020 and 2019 and moreover it offers forecast for the Covid-19 period from 2020 to 2028.The report provides COVID-19 impact on Anti-Cancer Drug market, global analysis, different challenges or threats and opportunities for stakeholders involved in the Anti-Cancer Drug market.

Report Opportunity: Global Anti-Cancer Drug Market

This report delivers an analytical examination of the Anti-Cancer Drug market summarized in broad sections such as
  1. Anti-Cancer Drug Market Summary
  2. Key Commercial Growths in the Anti-Cancer Drug Industry
  3. Market Dynamics Affecting the Anti-Cancer Drug Industry
  4. Important Market Trends and Future Development Scenario of the Anti-Cancer Drug Market
  5. Anti-Cancer Drug Market Revenue and Forecast, by Type, 2018 – 2028
  6. Competitive Landscape of Anti-Cancer Drug Industry
  7. Positioning of Main Market Players in the Anti-Cancer Drug Industry
  8. Anti-Cancer Drug Market Revenue and Forecast, by Application, 2018 - 2028
  9. Anti-Cancer Drug Market Revenue and Forecast, by End-use, 2018 - 2028
  10. Anti-Cancer Drug Market Revenue and Forecast, by Geography, 2018 - 2028
Anti-Cancer Drug Market Segmentation:

The report provides detailed examination of the Anti-Cancer Drug market on the basis of various segments such as type, application and end-use industry. The Anti-Cancer Drug market is segmented as follows:

Anti-Cancer Drug Market, by Type:
  • Avastin
  • Rituxan
  • Herceptin
  • Alimta
Anti-Cancer Drug Market, by Application:
  • Hospital
  • Clinic
  • Home Care
Geographic Coverage

The report on the Anti-Cancer Drug market delivers an in depth country-level cross-sectional analysis across different regions around the globe. The report comprises of complete market value and forecast for the following countries and regions:

North America Anti-Cancer Drug Market Revenue and Forecast
  • U.S.
  • Canada
Europe Anti-Cancer Drug Market Revenue and Forecast
  • UK
  • Germany
  • France
  • Rest of Europe
Asia Pacific Anti-Cancer Drug Market Revenue and Forecast
  • China
  • Japan
  • India
  • Rest of Asia Pacific
Latin America Anti-Cancer Drug Market Revenue and Forecast
  • Mexico
  • Brazil
  • Rest of Latin America
Middle East and Africa Anti-Cancer Drug Market Revenue and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Anti-Cancer Drug Market Snapshot
          2.1.1. Global Anti-Cancer Drug Market By Type,2019
               2.1.1.1.Avastin
               2.1.1.2.Rituxan
               2.1.1.3.Herceptin
               2.1.1.4.Alimta
          2.1.2. Global Anti-Cancer Drug Market By Application,2019
               2.1.2.1.Hospital
               2.1.2.2.Clinic
               2.1.2.3.Home Care
          2.1.3. Global Anti-Cancer Drug Market By End-use,2019
          2.1.4. Global Anti-Cancer Drug Market By Geography,2019

3. Global Anti-Cancer Drug Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Anti-Cancer Drug Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Anti-Cancer Drug Market Size (US$), By Type, 2018 – 2028

5. Global Anti-Cancer Drug Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Anti-Cancer Drug Market Size (US$), By Application, 2018 – 2028

6. Global Anti-Cancer Drug Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Anti-Cancer Drug Market Size (US$), By End-use, 2018 – 2028

7. Global Anti-Cancer Drug Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Anti-Cancer Drug Market Analysis, 2018 – 2028 
          7.2.1. North America Anti-Cancer Drug Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Anti-Cancer Drug Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Anti-Cancer Drug Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Anti-Cancer Drug Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Anti-Cancer Drug Market Analysis, 2018 – 2028 
          7.3.1.  Europe Anti-Cancer Drug Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Anti-Cancer Drug Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Anti-Cancer Drug Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Anti-Cancer Drug Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Anti-Cancer Drug Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Anti-Cancer Drug Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Anti-Cancer Drug Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Anti-Cancer Drug Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Anti-Cancer Drug Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Anti-Cancer Drug Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Anti-Cancer Drug Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Anti-Cancer Drug Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Anti-Cancer Drug Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Anti-Cancer Drug Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Anti-Cancer Drug Market Analysis, 2018 – 2028 
          7.6.1.  MEA Anti-Cancer Drug Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Anti-Cancer Drug Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Anti-Cancer Drug Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Anti-Cancer Drug Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Anti-Cancer Drug Providers
        8.4.1 Merck
                8.1.1 Business Description
                8.1.2 Merck Geographic Operations
                8.1.3 Merck Financial Information
                8.1.4 Merck Product Positions/Portfolio
                8.1.5 Merck Key Developments
        8.4.2 Bristol-Myers Squibb
                8.2.1 Business Description
                8.2.2 Bristol-Myers Squibb Geographic Operations
                8.2.3 Bristol-Myers Squibb Financial Information
                8.2.4 Bristol-Myers Squibb Product Positions/Portfolio
                8.2.5 Bristol-Myers Squibb Key Developments
        8.4.3 Bayer
                8.3.1 Business Description
                8.3.2 Bayer Geographic Operations
                8.3.3 Bayer Financial Information
                8.3.4 Bayer Product Positions/Portfolio
                8.3.5 Bayer Key Developments
        8.4.4 GlaxoSmithKline
                8.4.1 Business Description
                8.4.2 GlaxoSmithKline Geographic Operations
                8.4.3 GlaxoSmithKline Financial Information
                8.4.4 GlaxoSmithKline Product Positions/Portfolio
                8.4.5 GlaxoSmithKline Key Developments
        8.4.5 Novartis
                8.5.1 Business Description
                8.5.2 Novartis Geographic Operations
                8.5.3 Novartis Financial Information
                8.5.4 Novartis Product Positions/Portfolio
                8.5.5 Novartis Key Developments
        8.4.6 Sanofi
                8.6.1 Business Description
                8.6.2 Sanofi Geographic Operations
                8.6.3 Sanofi Financial Information
                8.6.4 Sanofi Product Positions/Portfolio
                8.6.5 Sanofi Key Developments
        8.4.7 Pfizer
                8.7.1 Business Description
                8.7.2 Pfizer Geographic Operations
                8.7.3 Pfizer Financial Information
                8.7.4 Pfizer Product Positions/Portfolio
                8.7.5 Pfizer Key Developments
        8.4.8 Amgen
                8.8.1 Business Description
                8.8.2 Amgen Geographic Operations
                8.8.3 Amgen Financial Information
                8.8.4 Amgen Product Positions/Portfolio
                8.8.5 Amgen Key Developments
        8.4.9 Celgene Corporation
                8.9.1 Business Description
                8.9.2 Celgene Corporation Geographic Operations
                8.9.3 Celgene Corporation Financial Information
                8.9.4 Celgene Corporation Product Positions/Portfolio
                8.9.5 Celgene Corporation Key Developments
        8.4.10 Ariad Pharmaceuticals
                8.10.1 Business Description
                8.10.2 Ariad Pharmaceuticals Geographic Operations
                8.10.3 Ariad Pharmaceuticals Financial Information
                8.10.4 Ariad Pharmaceuticals Product Positions/Portfolio
                8.10.5 Ariad Pharmaceuticals Key Developments
        8.4.11 Eli Lilly
                8.11.1 Business Description
                8.11.2 Eli Lilly Geographic Operations
                8.11.3 Eli Lilly Financial Information
                8.11.4 Eli Lilly Product Positions/Portfolio
                8.11.5 Eli Lilly Key Developments
        8.4.12 Hoffmann-La Roche Ltd.
                8.12.1 Business Description
                8.12.2 Hoffmann-La Roche Ltd. Geographic Operations
                8.12.3 Hoffmann-La Roche Ltd. Financial Information
                8.12.4 Hoffmann-La Roche Ltd. Product Positions/Portfolio
                8.12.5 Hoffmann-La Roche Ltd. Key Developments
        8.4.13 AstraZeneca
                8.13.1 Business Description
                8.13.2 AstraZeneca Geographic Operations
                8.13.3 AstraZeneca Financial Information
                8.13.4 AstraZeneca Product Positions/Portfolio
                8.13.5 AstraZeneca Key Developments
        8.4.14 Boehringer Ingelheim GmbH
                8.14.1 Business Description
                8.14.2 Boehringer Ingelheim GmbH Geographic Operations
                8.14.3 Boehringer Ingelheim GmbH Financial Information
                8.14.4 Boehringer Ingelheim GmbH Product Positions/Portfolio
                8.14.5 Boehringer Ingelheim GmbH Key Developments
        8.4.15 Teva Pharmaceuticals
                8.15.1 Business Description
                8.15.2 Teva Pharmaceuticals Geographic Operations
                8.15.3 Teva Pharmaceuticals Financial Information
                8.15.4 Teva Pharmaceuticals Product Positions/Portfolio
                8.15.5 Teva Pharmaceuticals Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Anti-Cancer Drug Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Anti-Cancer Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Anti-Cancer Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Anti-Cancer Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Anti-Cancer Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Anti-Cancer Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Anti-Cancer Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Anti-Cancer Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Anti-Cancer Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Anti-Cancer Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Anti-Cancer Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Anti-Cancer Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Anti-Cancer Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Anti-Cancer Drug Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Anti-Cancer Drug Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Anti-Cancer Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Anti-Cancer Drug: Market Segmentation 
FIG. 2 Global Anti-Cancer Drug Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Anti-Cancer Drug Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Anti-Cancer Drug Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Anti-Cancer Drug Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Anti-Cancer Drug Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Anti-Cancer Drug Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Anti-Cancer Drug Providers, 2019
FIG. 11 Global Anti-Cancer Drug Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Anti-Cancer Drug Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Anti-Cancer Drug Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Anti-Cancer Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Anti-Cancer Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Anti-Cancer Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Anti-Cancer Drug Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Anti-Cancer Drug Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Anti-Cancer Drug market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Market Value, By Segment1, 2018 – 2028
TABLE  North America Market Value, By Segment2, 2018 – 2028
TABLE  North America Market Value, By Country, 2018 – 2028
TABLE  Europe Market Value, By Segment1, 2018 – 2028
TABLE  Europe Market Value, By Segment2, 2018 – 2028
TABLE  Europe Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Market Value, By Country, 2018 – 2028
TABLE  Latin America Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Market Value, By Country, 2018 – 2028
TABLE  MEA Market Value, By Segment1, 2018 – 2028
TABLE  MEA Market Value, By Segment2, 2018 – 2028
TABLE  MEA Market Value, By Country, 2018 – 2028
 

List of Figures

FIG.  Global Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Market, By Geography, 2019 (US$ Mn)
FIG.  Global Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Providers, 2016
FIG.  Global Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  U.S. Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Market Value, 2018 – 2028, (US$ Mn)